 |
|
|
| |
MAGELLAN-2: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR IN LIVER OR RENAL TRANSPLANT ADULTS WITH CHRONIC HEPATITIS C GENOTYPE 1-6 INFECTION
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-22 Amsterdam Netherlands
Nancy Reau1, Paul Y. Kwo2, Susan Rhee3, Robert S. Brown, Jr.4, Kosh Agarwal5, Peter Angus6, Ed Gane7, Jia-Horng Kao8, Parvez S. Mantry9, K. Rajender Reddy10, Tram T. Tran11, Yiran B. Hu3, Abhishek Gulati3, Preethi Krishnan3, Emily O. Dumas3, Nancy S. Shulman3, Roger Trinh3, Xavier Forns12
1Rush University Medical Center, Chicago, IL, USA; 2Stanford University School of Medicine, Palo Alto, CA, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Weill Cornell Medical College, Center for Liver Disease and Transplantation, New York, NY, USA; 5Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK; 6University of Melbourne, Melbourne Australia; 7University of Auckland, Auckland, New Zealand; 8National Taiwan University Hospital, Taipei, Taiwan; 9The Liver Institute at Methodist Dallas, Dallas, TX, USA; 10University of Pennsylvania, Philadelphia, PA, USA; 11Cedars Sinai Medical Center, Los Angeles, CA, USA; 12Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS, Barcelona, Spain
|
| |
|
|
|
|
|
